Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.41

0.0%

Nov 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (724)	9/11/2000 3:17:36 PM
From: rkrw	Read Replies (3) of 1475

Rick, Well, I was there :-) Eliot mentioned RA, Crohn's and MS in passing. I don't think he was implying that any clinical plans were imminent. He did imply that these were potential future areas of medi-507 development. Let's not forget, those decisions are in MEDI's hands. XOMA jumped by about $200M in market cap on some positive brokerage comments revolving around its psoriasis compound. BTRN is sitting here at a $160M market cap. How competitive will Medi-507 be with anti-CD11a?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next